Pharma BD Deal Intelligence
Takeda paid $8.8B for Millennium—then the largest overseas acquisition by a Japanese pharma—gaining Velcade, the proteasome inhibitor that became standard of care in multiple myeloma. The deal established Takeda's US oncology presence and organizational foundation for its later $62B Shire acquisition.
Velcade franchise anchored Takeda U.S. oncology transformation with $20B+ lifecycle revenue
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Takeda acquired Millennium Pharmaceuticals for $8.8B for cancer drug research, including Velcade.
Takeda buys Millennium to build its U.S. business, with the acquisition accelerating Takeda's vision of becoming a global leader in oncology with critical mass…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda Pharmaceutical Co. acquired Millennium Pharmaceuticals for $25 per share (~$8.8 billion) in an all-cash tender offer, gaining Velcade (bortezomib) for multiple myeloma ($528M in 2007 revenue) and establishing a major US oncology presence. This was the largest overseas acquisition by a Japanese pharmaceutical company at the time.
Entyvio (vedolizumab) is the commercial franchise cornerstone of Takeda's GI portfolio and competes in moderate-to-severe ulcerative colitis (UC) against multiple MOA classes. Anti-alpha4beta7 integrin (direct MOA): Entyvio itself has no direct MOA competitor marketed; natalizumab (Tysabri, Biogen; anti-alpha4 broader) is not used in UC due to PML risk. TNF inhibitors: infliximab (Remicade, Janssen; biosimilars Inflectra, Renflexis, Avsola), adalimumab (Humira, AbbVie; biosimilars), golimumab (Simponi, Janssen) are the legacy biologic standard. IL-12/23 and IL-23p19 inhibitors: ustekinumab (Stelara, J&J), mirikizumab (Omvoh, Lilly; FDA-approved UC Oct 2023), risankizumab (Skyrizi, AbbVie; FDA-approved UC June 2024). JAK inhibitors: tofacitinib (Xeljanz, Pfizer; UC 2018), upadacitinib (Rinvoq, AbbVie; UC March 2022). S1P modulators (oral, emerging class): ozanimod (Zeposia, BMS; UC May 2021) and etrasimod (Velsipity, Pfizer; UC October 2023). Pipeline anti-TL1A: tulisokibart (MK-7240, Merck) and duvakitug (TEV-48574, Teva/Sanofi) in Phase III. Entyvio reported ~$7.9B global FY2023 revenue (Takeda FY2023 annual report), of which UC is the larger share. For a commercial lead, Entyvio's UC franchise is most threatened by the IL-23p19 wave plus oral S1P modulators that obviate infusion burden.
Velcade (bortezomib) anchors the multiple myeloma (MM) treatment backbone but has faced generic competition since 2017 and mechanistic displacement by newer targeted classes. Proteasome inhibitors (direct MOA class): bortezomib (Velcade, Takeda; multiple generics) in VRd/KRd induction; carfilzomib (Kyprolis, Amgen) in second-line Kd and KRd combos — ~$1.3B 2023 US revenue (Amgen 10-K); ixazomib (Ninlaro, Takeda) as oral PI in triplet regimens. Anti-CD38 monoclonal antibodies (dominant class in newly diagnosed and R/R): daratumumab (Darzalex / Darzalex Faspro, J&J/Genmab) — Darzalex franchise ~$13.3B FY2024 (J&J 10-K); isatuximab (Sarclisa, Sanofi). IMiDs (backbone): lenalidomide (Revlimid, BMS; generics launched 2022), pomalidomide (Pomalyst, BMS; generics 2024). BCMA-targeted cellular/bispecific therapies: idecabtagene vicleucel (Abecma, BMS/2seventy), ciltacabtagene autoleucel (Carvykti, J&J/Legend), teclistamab (Tecvayli, J&J; BCMAxCD3), elranatamab (Elrexfio, Pfizer), talquetamab (Talvey, J&J; GPRC5DxCD3). BCL-2 inhibitor: venetoclax (Venclexta, AbbVie; off-label MM t(11;14)). For a commercial lead, bortezomib is effectively a generic backbone with limited branded franchise value; the anti-CD38 class plus BCMA cellular therapies define the current competitive frontier.
Velcade (bortezomib) competes in mantle cell lymphoma (MCL), where the treatment paradigm has shifted decisively from proteasome-inhibitor-anchored combinations to covalent BTK inhibitors and, most recently, cellular therapy. Proteasome inhibitors (direct MOA class): bortezomib (Velcade, Takeda; multiple generics since 2017) remains part of VR-CAP induction per the LYM-3002 trial; carfilzomib (Kyprolis, Amgen) and ixazomib (Ninlaro, Takeda) have not gained MCL indication traction. Covalent BTK inhibitors (current dominant MOA): ibrutinib (Imbruvica, AbbVie/J&J; voluntarily withdrew MCL accelerated approval 2023 after SHINE and follow-up), acalabrutinib (Calquence, AstraZeneca; FDA-approved R/R MCL), zanubrutinib (Brukinsa, BeiGene; FDA-approved R/R MCL) — this class is the primary franchise threat. Non-covalent BTK: pirtobrutinib (Jaypirca, Lilly) approved in post-covalent-BTK MCL Jan 2023. CAR-T (different class): brexucabtagene autoleucel (Tecartus, Gilead/Kite) FDA-approved for R/R MCL July 2020. Bispecifics/emerging: glofitamab (Columvi, Roche; MCL trials). Anti-CD20: rituximab (Rituxan, Roche; biosimilars Ruxience, Truxima) is backbone in R-CHOP/VR-CAP. For a commercial lead, Velcade's MCL franchise is almost fully generic and residual; the MCL market is now BTKi-plus-CAR-T driven.
Entyvio (vedolizumab) competes in moderate-to-severe Crohn's disease (CD) where its gut-selective alpha4beta7 integrin MOA sits against multiple biologic and small-molecule classes. TNF inhibitors (legacy standard of care): infliximab (Remicade, Janssen; biosimilars Inflectra, Renflexis, Avsola), adalimumab (Humira, AbbVie; 10+ biosimilars), certolizumab pegol (Cimzia, UCB) dominate first-line biologic volume. IL-12/23 and IL-23p19 inhibitors: ustekinumab (Stelara, J&J; biosimilars launching 2025), risankizumab (Skyrizi, AbbVie; FDA-approved CD June 2022), mirikizumab (Omvoh, Lilly; CD approval Jan 2025) are the fastest-growing competitor class and have shown superiority over ustekinumab in SEQUENCE. JAK1 inhibitors: upadacitinib (Rinvoq, AbbVie; FDA-approved CD May 2023) is a second-line oral option with strong efficacy but boxed-warning headwinds. Anti-TL1A (pipeline direct MOA threat to Entyvio's 'differentiated-mechanism' positioning): tulisokibart (MK-7240, Merck) and duvakitug (TEV-48574, Teva/Sanofi) in Phase III. For a commercial lead, Entyvio generated ~$7.9B global FY2023 sales (Takeda FY2023 annual report), predominantly from UC; CD is the more contested segment, and Entyvio's near-term franchise threat in CD is Skyrizi's rapid uptake plus biosimilar Stelara.
Takeda Pharmaceutical Co. closes acquisition/merger of Millennium Pharmaceuticals for $8.8B, establishing strategic position and initiating integration.
Takeda acquired Millennium for $8.8B gaining Velcade ($3B+ peak sales) which became the foundation of Takeda Oncology global transformation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals (this deal) | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2003 deals · Takeda Pharmaceutical Company Ltd. deals · Gastroenterology deals